Integrated Care Pathway (ICP) for the. Management of clozapine COMMUNITY INITIATION
|
|
- Domenic Fisher
- 5 years ago
- Views:
Transcription
1 Document Reference MM 049 Integrated Care Pathway (ICP) for the Management of clozapine COMMUNITY INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant Allergies One booklet to be completed for each patient initiated on clozapine treatment Approved the Horizon Scanning and Prescribing Guidance sub group 23 November 2012 Review date: 23 November 2015 G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
2 Contents Page 1 Pre-initiation phase of clozapine 3 - Checklist 2 Routine baseline assessment 4 3 Decision processes for initiation of clozapine 5 4 Rationale 5 5 Community initiation pathway Titration 5.2 Monitoring and observations 6 Community initiation standard regime 7 7 Community initiation pathway observation record 8 11 Appendix 1 Clozapine initiation observations information 12 Appendix 2 Clozapine home treatment care plan Appendix 3 Appendix 4 Appendix 5 Appendix 6 Community initiation of clozapine treatment prescription Day 1 7 Community initiation of clozapine treatment prescription Day 8 14 Community initiation of clozapine treatment prescription Day Community initiation of clozapine treatment prescription Day G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
3 PRE-INITIATION PHASE 1 Pre-initiation phase of clozapine. A full description for the initiation of clozapine is given in the Summary of Product Characteristics (SPC) for Clozaril. All staff involved in this process should familiarise themselves fully with these guidelines. Pre-initiation checklist Does the patient have a diagnosis of treatment resistant schizophrenia? Has the patient been prescribed two previous antipsychotic agents, including a second generation antipsychotic, for a minimum of six weeks each? Does the patient fulfil the criteria for other indications as per the SPC? - Severe, untreatable neurological adverse reactions to other antipsychotic agents. - Psychotic disorders occurring during the course of Parkinson s Disease, where standard treatment has failed. - Has there been a full multidisciplinary meeting to discuss initiation as per CPA policy (Consultant Psychiatrist, Care Coordinator and other interested/involved parties)? Has the clinical team given consideration to the identified contra-indications to the use of clozapine? YES NO Contraindications (SPC Clozaril Novartis Pharmaceuticals UK) Patients unable to undergo regular blood tests. History of toxic or idiosyncratic granulocytopenia/agranulocytosis (with the exception of granulocytopenia/ agranulocytosis from previous chemotherapy). History of clozapine-induced agranulocytosis. Impaired bone marrow function. Uncontrolled epilepsy. Alcoholic and other toxic psychoses, drug intoxication, comatose conditions. Circulatory collapse and/or CNS depression of any cause. Severe renal or cardiac disorders (e.g. myocarditis). Active liver disease associated with nausea, anorexia or jaundice; progressive liver disease, hepatic failure. Paralytic ileus. Has the General Practitioner been contacted to determine any concurrent physical health concerns/investigations/treatments, and the use of any other prescribed medications as per Procedure for medicines reconciliation on admission of patients to hospital (MM 026)? Clozapine treatment must not be started concurrently with drugs known to have a G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
4 substantial potential for causing agranulocytosis; concomitant use of depot antipsychotics is to be discouraged. PLEASE NOTE: If the answers to the questions above contraindicate the initiation of clozapine treatment, please refer to the following points: If the answers to the check list above are specifically contraindicated the Clozaril Patient Monitoring System (CS) the patient must not be commenced on clozapine and must be referred back to the Consultant If there is a complexity issue or unlicensed use issue then a further multidisciplinary team (MDT) meeting is called, the issues are discussed and a decision made regarding inpatient or community initiation of clozapine. 2 Routine Baseline Assessment Full medical and psychiatric history (including previous treatment concordance). Physical examination: weight, height, pulse, blood pressure (sitting and standing), temperature, and waist circumference Electrocardiogram Completed Blood tests Full blood count Differential white cell count LFTs U & Es Lipids TFTs Random blood glucose Troponin I or T CRP Medicines reconciliation GP contacted to advise of all medications prescribed and any other physical health concerns/treatments Substance history including alcohol, smoking, caffeine, illicit substances Details: - COMPLETE BASELINE OBSERVATIONS using Community Initiation Pathway Observation Record (Page 8). G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
5 3 Decision Processes for the initiation of clozapine YES NO Patient agreeable to initiation of treatment? Carers present? Carers agreeable to support initial treatment regime? Diagnosis confirmed? Physical health acceptable? Bloods taken and within acceptable ranges? Consent obtained? Decision to initiate treatment? Inpatient initiation Outpatient initiation 4 Rationale Concurrent processes prior to initiation of clozapine. Check that the following has been completed: - Completed Inform pharmacy department/ mental health pharmacist. Inform CS and obtain registration number Inform clozapine clinic of intention to treat Inform General Practitioner (GP) (See GP support pack) G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
6 COMMUNITY INITIATION PATHWAY 5 Community initiation pathway YES NO Patient is aware of the need for daily attendance/ home visit Home Treatment (HT) Team? A Clozapine Home Treatment Care Plan has been completed and is in place? (See APPENDIX ) GP has been informed of clozapine start date? A carer/ relative should stay with the patient overnight and this has been agreed? Contact numbers have been given? (HT Team, CS advice line, GP, Nurse on Block/ Wards) The patient has a GREEN result from CS? The Community Initiation of Clozapine Treatment Prescription Day 1 7 has been completed and dispensed pharmacy ready for Day 1 [insert day of the week]? An observation record has been completed and is in place? 5.1 Titration Dependant on tolerability and results of physical observations, it may be necessary to slow down the titration regime in some cases. 5.2 Monitoring and observations. Complete Clozapine Initiation Observations (Appendix 1) Complete Community Initiation Pathway Observation Record (Page 8) It is imperative that observations are undertaken when initiating clozapine in community settings as robustly as in inpatient settings. The team responsible for community initiation will stay with the patient for the 6 hours necessary to complete all observations. A review will be undertaken the SHO/SHO on call/advanced Practitioner. If observations are stable and following review, the patient can be at home with family/carer support with advice to contact HT Team/attend A&E/other if necessary and as appropriate. A Home Treatment Care Plan must be completed and in place before the patient returns home. (See Appendix 2). Please also refer to Guidelines for the monitoring of physical health for patients taking clozapine (MM 042) G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
7 6 Community Initiation Dose Regime. Pre-initiation checks complete and baseline assessments fully completed and ready to start on first day of initiation. This should always be Tuesday to take weekends into account for supplies of medication. The Advanced Practitioner/ SHO clerks in patient and takes initial blood samples to ensure a green blood result is obtained from CS before initiation begins. Result from CS. Result / Date The and monitoring regime outlined below is a guide to treatment as recommended the manufacturer of Clozaril, Novartis, and is available via the website and the Clozaril Patient Monitoring Service (CS). Monitoring and observation of the patient should be undertaken as outlined in the table from page 8. The first Community Initiation of Clozapine Treatment Prescription for Day 1 7, must be completed the prescriber and issued pharmacy when a green result is obtained and before treatment begins. Subsequent prescriptions to be completed as required (Appendix 3 6) or complete the inpatient prescription chart and variable section, and request supplies from pharmacy using an outpatient prescription. Advanced Practitioner/ SHO to review patient prior to leaving department. When observations remain within normal range and the patient is stable on the regime, observations may be stopped. A discussion must take place with the Consultant to confirm that the observations and are stable. At this point the patient will normally be discharged from the HT into care of the care co-ordinator and Consultant unless an alternative arrangement has previously discussed and agreed the Advanced Practitioner/SHO. The patient should be monitored through the current clozapine clinic pathway and via the GP. Blood tests should be taken on Days 1, 8, 15 and 22. Medical and pharmacy review twice a week on initiation and weekly thereafter. Day Morning Evening Day Morning Evening 1 Tuesday 12.5mg NIL 15 Tuesday 100mg 125mg 2 Wednesday 25mg NIL 16 Wednesday 100mg 150mg 3 Thursday 37.5mg NIL 17 Thursday 100mg 175mg 4 Friday 50mg NIL 18 Friday 100mg 200mg 5 Saturday 50mg NIL 19 Saturday 100mg 200mg 6 Sunday 50mg NIL 20 Sunday 100mg 200mg 7 Monday 75mg NIL 21 Monday 100mg 250mg 8 Tuesday 50mg 50mg 22 Tuesday 100mg 250mg 9 Wednesday 50mg 75mg 23 Wednesday 100mg 250mg 10 Thursday 75mg 75mg 24 Thursday 100mg 250mg 11 Friday 75mg 100mg 25 Friday 100mg 300mg 12 Saturday 75mg 100mg 26 Saturday 100mg 300mg 13 Sunday 75mg 100mg 27 Sunday 100mg 300mg 14 Monday 100mg 100mg 28 Monday 100mg 300mg G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
8 7 Community Initiation Pathway Observation Record BP Temperature Pulse Observations Sitting Standing Baseline DAY 1 DATE. (Tuesday) Pre 15 mins post Hourly for 6 hours post 1 hour 2 hours 3 hours 4 hours 5 hours 6 hours Pre 15 mins post Hourly for 6 hours post 1 hour 2 hours 3 hours 4 hours 5 hours 6 hours DAY 2 Date..(Wednesday) G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
9 BP Temperature Pulse Observations Sitting Standing 3 Thur 4 Fri 5 Sat 6 Sun 7 Mon 2 hours post 6 hours post 2 hours post 6 hours post 2 hours post 6 hours post 2 hours post 6 hours post 2 hours post 6 hours post DAY 3 to 7 DAY 8 to 14 G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
10 8 Tues 9 Wed 10 Thur 11 Fri CRP check Troponin I or T check G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
11 12 Sat DAY 8 to 14 Cont d Sitting BP Temperature Pulse Observations Standing 13 Sun 14 Mon G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
12 DAY 15 to Tues 16 Wed 17 Thur 18 Fri 19 Sat 20 Sun 21 Mon 22 Tues 23 Wed 24 Thur 25 Fri 26 Sat 27 Sun 28 Mon 29 Tue 57 Tue CRP check CRP check CRP check CRP check Troponin I or T check Troponin I or T check Troponin I or T check Troponin I or T check G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
13 APPENDIX 1 Clozapine Initiation Observations Information Baseline blood pressure, pulse and temperature should be known. Observations should be taken prior to the first, 15 minutes after and every hour up to six hours, as a minimum, after the first, on DAY ONE and DAY TWO. Parameters Take action if: - Blood pressure Systolic < 100 or > 170 (Sitting and Diastolic < 60 or > 100 standing) OR a postural drop of 30mmHg Pulse Temperature > 100bpm (> 120bpm or increased 30bpm repeat ECG) > 38.4 degrees C OR < 35.5 degrees C Repeat the observations if outside the above parameters after 15 minutes. If still outside the above parameters call the doctor for advice. Only omit the if the doctor or pharmacist advises to do so. Observations for subsequent s - Immediately prior to each titration until stabilisation. G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
14 APPENDIX 2 Clozapine Home Treatment Care Plan Surname Forenames DOB RT Date Address Diagnosis Name Address & Contact numbers Plan copied to (tick) Patient See above See above Main Carer Consultant Social Worker CPN GP Others Next of Kin G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
15 Medication Dose Frequency Indication Issues (side effects, concurrence etc) Clozapine (Clozaril) Increasing Daily Antipsychotic Patients commencing clozapine require careful monitoring. This is due to side effects which will be discussed with XXXX and their carer along with the appropriate action to be taken. EMERGENCY CONTACT NUMBERS Home Treatment Team (HT) GP Clozaril Patient Monitoring Service (CS) CRISIS PLAN: Action to be taken, patient and HT team responsibilities Should XXXX develop any of the serious side effects of clozapine such as fever sore throat rash or other signs of infection extremely high pulse rate or fainting INFORM HT. TE Stop clozapine. Take FBC blood test. If HT are unable to respond XXXX should attend A&E department stating that clozapine is being taken, the, and the symptoms they are concerned about. IMMEDIATE attendance to A&E if the following side effects occur: seizure palpitations chest pain difficulty breathing extremely high pulse rate for a long period of time INFORM CRHT. Patient given copy of HT information sheet (please circle) Yes No G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
16 IDENTIFIED NEED INTERVENTIONS ACHIEVED XXXX is to commence clozapine whilst in the community. To ensure safe initiation of clozapine and monitor its effects and side effects HT team to arrange pre commencement checks and tests. As a minimum this will include WBC, LFT U&E, Cholesterol, Glucose, TFT, and an ECG, Troponin I or T, CRP. These must be carried out within 10 days of commencing clozapine. Clozapine initiation will start on a [insert day of the week] either in the patient s own home or in a treatment suite where available. On the first 2 days XXXX will be monitored for 6 hours CRHT staff. BP, Pulse and Temperature will be monitored pre-, then hourly a RMN. XXXX will be able to be at home after the 6 hours only if agreed the Advanced Practitioner/ SHO. If there are any concerns a Dr should be informed. A blood test will be required on Day 3 to be arranged CRHT. From Day 3 XXXX will be monitored at home. This will mean that a responsible adult must be with XXXX for 24 hours a day. The HT team will visit 4 times daily. Visit 1 to take BP, pulse and Temperature and monitor any other side effects, then administer the of clozapine. HT team will then visit 2 and 6 hours after this to check BP, Pulse and Temperature. A further visit will be carried out in the evening, to check side effects and observations Day 3-7 There will be 4 visits as described above. Day 8-14 Observations will be required to be taken once, with there being 2 visits a day ( & ) Day One visit per day to check observations. If on stable and no unacceptable side effects, XXXX will be discharged from HT team and into the care of the Clozapine Clinic and their care co-ordinator. During the course of clozapine initiation, regular blood tests will be required, a minimum of once per week. These will be arranged HT team. Cont d.. G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
17 IDENTIFIED NEED INTERVENTIONS ACHIEVED Clozapine is known to have certain side effects, which are manageable, these are symptoms such as constipation, excessive salivation, weight gain XXXX to be educated regarding the common side effects of clozapine XXXX to be encouraged to consume a high fibre diet. Along with avoiding processed, high fat foods. Should constipation become an issue, XXXX to inform the team so that medical staff can review and prescribe appropriate treatment. Hyper-salivation ( drooling ) This is a common side effect of clozapine and can be managed use of other medication. XXXX to inform the team if this occurs. XXXX to be educated regarding healthy eating and exercise as a means for reducing/preventing weight gain. It is also important that XXXX monitors their weight and is reviewed the medical team for signs of metabolic syndrome, where weight increases, along with raised cholesterol, blood glucose and blood pressure. Clozapine can often cause sedation. Whilst this can be difficult to combat, it is usually a temporary side effect and will diminish over time. Regular exercise, healthy eating and good sleep hygiene can help reduce the effect of sedation. Blood tests and result monitoring: Clozapine requires regular blood monitoring At least once per week during the first 18 weeks. HT team to arrange the pre clozapine blood test and ensure XXXX is registered with CS. This will enable the initial prescription of clozapine to be completed A further test will be required on Day 3. After this blood tests will be required every [insert day of the week]. Clozapine will be prescribed on a weekly basis, assuming that the blood results are green If there is an amber result there must be a repeat blood test performed as soon as possible. If there is a red result, clozapine must be stopped and urgent repeat bloods taken. XXXX should be aware of the frequency of bloods tests and that additional tests may be required at the medical team s request. Clozapine will then be released from the hospital pharmacy on a [insert day of the week]. HT team will usually arrange for this to be collected. G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
18 REVIEW Date Comments Patient signature: Date: HT team practitioner Signature: Date: G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
19 COMMUNITY INITIATION OF CLOZAPINE TREATMENT PRESCRIPTION APPENDIX 3 DAY 1 TO 7 (inclusive) To the Prescriber To Pharmacy If an alternate to the standard CS recommended is required, the printed must be crossed through clearly and the new written in the change to column, each change must be initialled before the prescription is signed and dated. Please dispense sufficient tablets/ liquid for the s stated below and photocopy this prescription for your records, returning the complete book with the medication supplied. Please label with directions or supply reminder card. Patient name: DOB: Result from CS (include date) DAY DATE MORNING DOSE CS Change to Initials Dose administered Time Observations Completed CS Sign Tues mg NIL Weds 2 25mg NIL Thurs mg NIL Fri 4 50mg NIL Sat 5 50mg NIL Sun 6 50mg NIL Mon 7 75mg NIL Prescriber signature Print name Date Bleep/ contact tel. no. EVENING DOSE Change to PHARMACY USE ONLY Dispensed : Checked : Date dispensed: Initials Dose administered Time Sign Quantity supplied: 25mg tablets 100mg tablets Liquid 100mg/5ml Observations Completed G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
20 COMMUNITY INITIATION OF CLOZAPINE TREATMENT PRESCRIPTION APPENDIX 4 DAY 8 TO 14 (inclusive) To the Prescriber To Pharmacy If an alternate to the standard CS recommended is required, the printed must be crossed through clearly and the new written in the change to column, each change must be initialed before the prescription is signed and dated. Please dispense sufficient tablets/ liquid for the s stated below and photocopy this prescription for your records, returning the complete book with the medication supplied. Please label with directions or supply reminder card. Patient name: DOB: Result from CS (include date) DAY DATE MORNING DOSE CS Change to Initials Dose administered Time Observations Completed CS Sign Tues 8 50mg 50mg Weds 9 50mg 75mg Thurs 10 75mg 75mg Fri 11 75mg 100mg Sat 12 75mg 100mg Sun 13 75mg 100mg Mon mg 100mg Prescriber signature Print name Date Bleep/ contact tel. no. EVENING DOSE Change to PHARMACY USE ONLY Dispensed : Checked : Date dispensed: Initials Dose administered Time Sign Quantity supplied: 25mg tablets 100mg tablets Liquid 100mg/5ml Observations Completed G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
21 COMMUNITY INITIATION OF CLOZAPINE TREATMENT PRESCRIPTION APPENDIX 5 DAY 15 TO 21 (inclusive) To the Prescriber To Pharmacy If an alternate to the standard CS recommended is required, the printed must be crossed through clearly and the new written in the change to column, each change must be initialed before the prescription is signed and dated. Please dispense sufficient tablets/ liquid for the s stated below and photocopy this prescription for your records, returning the complete book with the medication supplied. Patient name: DOB: Result from CS (include date) DAY DATE MORNING DOSE CS Change to Initials Dose administered Time Observations Completed CS Sign Tues mg 125mg Weds mg 150mg Thurs mg 175mg Fri mg 200mg Sat mg 200mg Sun mg 200mg Mon mg 250mg Prescriber signature Print name Date Bleep/ contact tel. no. EVENING DOSE Change to PHARMACY USE ONLY Dispensed : Checked : Date dispensed: Initials Dose administered Time Sign Quantity supplied: 25mg tablets 100mg tablets Liquid 100mg/5ml Observations Completed G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
22 COMMUNITY INITIATION OF CLOZAPINE TREATMENT PRESCRIPTION APPENDIX 6 DAY 22 TO 28 (inclusive) To the Prescriber To Pharmacy If an alternate to the standard CS recommended is required, the printed must be crossed through clearly and the new written in the change to column, each change must be initialed before the prescription is signed and dated. Please dispense sufficient tablets/ liquid for the s stated below and photocopy this prescription for your records, returning the complete book with the medication supplied. Patient name: DOB: Result from CS (include date) DAY DATE MORNING DOSE CS Change to Initials Dose administered Time Observations Completed CS Sign Tues mg 250mg Weds mg 250mg Thurs mg 250mg Fri mg 300mg Sat mg 300mg Sun mg 300mg Mon mg 300mg Prescriber signature Print name Date Bleep/ contact tel. no. EVENING DOSE Change to PHARMACY USE ONLY Dispensed : Checked : Date dispensed: Initials Dose administered Time Sign Quantity supplied: 25mg tablets 100mg tablets Liquid 100mg/5ml Observations Completed G/TGH/HQSecs/TD/LS/Clinical procedures/clozapine ICP. Community initiation. Version 2. Amended January of 22
Integrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION
Document Reference MM 048 Integrated Care Pathway (ICP) for the Management of clozapine INPATIENT INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant
More informationInitiation of Clozapine Treatment Community Patients
Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A Initiation of Clozapine Treatment for Patients in the
More informationThe licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia.
1. Introduction Future Directions CIC will support the use of the antipsychotic Clozapine in all appropriate cases. The purpose of this procedure is to set out the standards for Clinicians, Pharmacists,
More informationPolicy & Procedures Committee Date: 18 January 2018
Clinical SOP Out-patient Clozapine Initiation Procedure SOP Document Control Summary Status: Replacement supersedes Clozapine Policies and Procedures Version: v1.0 Date: October 2017 Hayley Smart Mo Azar
More informationClozapine intramuscular (IM) Guideline, inpatients only
SH CP 203 Clozapine intramuscular (IM) Guideline, inpatients only Summary: Guideline for use and monitoring of intramuscular clozapine treatment. Keywords: Target Audience: Clozapine, intramuscular, IM,
More informationClozapine Service Standards
Clozapine Service Standards Policy Number: MHP SUM Oct 2013 Implementation Date: Nov 2013 First Review Date: Nov 2015 Review Frequency: Bi-Annual The MHS Clozapine Review Group is responsible for monitoring
More informationClozapine Outpatient initiation
Clozapine Outpatient initiation 1. Introduction The licence for clozapine enables commencement of clozapine as an outpatient. Hospital admission for initiating clozapine has been recommended in the past
More informationClinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents
Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationSTARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.
STARTING PATIENTS ON AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. Indication: AA-CLOZAPINE (clozapine) is indicated in the management
More informationPOLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016
POLICY DOCUMENT Document Title High dose and combination antipsychotic guidance Reference Number n/a Policy Type Prescribing and Treatment Guideline Electronic File/Location Clinical Resources/Pharmacy/Prescribing
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationGENERAL PRACTITIONER (GP) SUPPORT PACK
Document Reference MM 050 Integrated Care Pathway (ICP) for the Management of clozapine GENERAL PRACTITIONER (GP) SUPPORT PACK One pack to be printed for each patient initiated on clozapine treatment,
More informationClaire Thomas, Deputy Chief Pharmacist. Tim Donaldson, Trust Chief Pharmacist. Contents. Section Description Page No.
Pharmacological Therapy Policy Practice Guidance Note Safe Prescribing of Clozapine V02 Version issued Issue 1 Jan 16 Issue 2 Nov 16 Planned review January 2019 PPT-PGN-05 Part of NTW(C)38 Pharmacological
More informationClozapine Prescribing and Monitoring Guideline
Document level: Trustwide (TW) Code: MP5 Issue number:6 Clozapine Prescribing and Monitoring Guideline Lead executive Authors details Type of document Target audience Document purpose Dr A Sivananthan
More informationGuideline for the In-patient initiation of Clozaril (Clozapine) within CWPT
Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT Version: 1 Author: Ambreena Asghar Designation: Pharmacist Responsible Director: Sharon Binyon Approved By: Drugs and Therapeutics
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationNorth Central London Medicines Optimisation Committee
North Central London Medicines Optimisation Committee Guidance for Pharmacy Staff Managing Clozapine For Patients Admitted to Acute Hospitals Disclaimer This guideline is registered at North Central London
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationlithium record book This record book contains information that will also be held in your patient records.
lithium record book This record book contains information that will also be held in your patient records. lithium record book This record book contains information that will also be held in your patient
More informationHigh Dose Antipsychotic Therapy (HDAT) guideline
Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857
More informationProcedure and Guidance for the use of Clozapine
Procedure and Guidance for the use of Clozapine Version: 2.1 Ratified by: Drugs & Therapeutics Group Date ratified: April 2015 Date issued: August 2015 (minor amendment Dec 15) Next Review Date: August
More informationCLOZAPINE TREATMENT GUIDELINES MARCH 2017
CLOZAPINE TREATMENT GUIDELINES MARCH 2017 0 Policy title Clozapine treatment guidelines Policy PHA06 reference Policy category All clinical staff who deal with medication in the Trust. Relevant to Clinical
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine
Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file
More informationHIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT)
HIGH DOSE ANTIPSYCHOTIC GUIDELINES (HDAT) Document Reference Version Number 2.00 High Dose Antipsychotic Guidelines (HDAT) G376 Author/Lead Job Title Jackie Stark Principal Pharmacist Clinical Services
More informationGuidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)
E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationADULT PRE-EXERCISE SCREENING TOOL
ADULT PRE-EXERCISE SCREENING TOOL This screening tool does not provide advice on a particular matter, nor does it substitute for advice from an appropriately qualified medical professional. warranty of
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationHave you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider.
Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider. 1 Benefits of Clozapine Clozapine may work when other medications don t. Doctors
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationPOLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011
POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE September 2011 WHSCT Policy for the safe use of oral methotrexate in secondary care Page 1 of 8 Policy Title Policy for the safe use of oral
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationClozapine Clinic Treatment Centre, St Georges Park
Clozapine Clinic Treatment Centre, St Georges Park Patient Information Leaflet Shining a light on the future This leaflet is relevant to the following clinic: St Georges Park Hospital Morpeth Northumberland
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationClozapine an introduction to treatment
Clozapine an introduction to treatment Pharmacy Department If at any time you have run out of tablets, or are concerned that you may run out, please contact the number below as soon as possible: A member
More informationS H A R E D P R E S C R I B I N G G U I D E L I N E
S H A R E D P R E S C R I B I N G G U I D E L I N E Introduction This shared prescribing guideline for the second generation antipsychotic medications listed above has been developed with due consideration
More informationLow risk upper GI bleeding pathway
Low risk upper GI bleeding pathway Background Low risk upper GI bleeding may be safely managed without an emergency admission to NUH following presentation to the ED. NUH uses the Glasgow Blatchford score
More informationNHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS Date 20 th November 2014 Our Ref HDAT_MGPG/Nov14 Enquiries to Caroline Hind Extension 56088 Direct Line 01224 556088 Email caroline.hind2@nhs.net
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside
More informationMental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service
Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact
More informationPhysical Activity and Diabetes Appendix
UNIT ONE LESSON 3: Physical Activity and Diabetes Appendix 9-WEEK PLAN FOR PHYSICAL ACTIVITY DO NOT BEGIN A PHYSICAL ACTIVITY PROGRAM UNTIL YOU HAVE MEDICAL CLEARANCE FROM YOUR DOCTOR. WEEKS 1 AND 2 Start
More informationClozapine, neutropenia and agranulocytosis, red alert management
Clozapine, neutropenia and agranulocytosis, red alert management The information in this document is not intended as a definitive treatment strategy, but as a suggested approach for clinicians. It is based
More informationINFLECTRA Infliximab Infusion 1,2 & 3
DEPARTMENT OF RHEUMATOLOGY DAY CASE ADMISSION RECORD PATIENT DAY CASE BOOKING REQUEST To be completed by Consultant, Registrar requesting day case Admission Hospital No. Surname Forename Address INFLECTRA
More informationClozapine Shared Care Protocol And Information For Oxfordshire GPs
Clozapine Shared Care Protocol And Information For Oxfordshire GPs There should be willing consent of all parties to enter into a shared care agreement. This includes patients (plus carers if necessary)
More informationURN: Family name: Given name(s): Address: Initial Signature Print Name Role
Do Not Write in this binding margin v5.00-02/2012 Mat. No.: 10206019 SW030b The State of Queensland (Queensland Health) 2012 Contact CIM@health.qld.gov.au ÌSW030bIÎ Facility: s Never Replace Clinical Judgement
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationThrombosis and Anticoagulation Team. Warfarin. Information for patients, relatives and carers
Thrombosis and Anticoagulation Team Warfarin Information for patients, relatives and carers What is warfarin? Warfarin is an anticoagulant. Anticoagulants are drugs which prevent harmful blood clots forming
More informationPatient Profile. Patient s details Initials: IF Age: 40 Gender: Male. Weight: 139.7kg Height: 510 metres BMI: >47
Patient Profile Patient background and medication list Reason for selecting profile Interesting depression case whereby there were several opportunities for intervention as a pharmacist to ensure drug-related
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationPROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE
PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE BRIEF OUTLINE OF THIS PROCEDURE This procedure sets out the requirements for prescribing,
More informationPATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists
PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationThis shared care protocol covers when atypical antipsychotics are prescribed for the treatment of
SHARED CARE PROTOCOL for ATYPICAL ANTIPSYCHOTICS SCOPE Greater Manchester West Mental health NHS Foundation Trust Bolton Primary Care Trust Salford Primary Care Trust Trafford Primary Care Trusts Issue
More informationPersonal Calendar Tracker
Personal Calendar Tracker The Personal Calendar Tracker was created as a companion to the Patient and Family Reference Handbook, which was developed for people living with kidney cancer and their families.
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationConsultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off
Policy For The Adjustment Of Insulin Injections By Paediatric Diabetes Specialist Nurses/Community Paediatric Nurses Diabetes Working With Children Within NHS Grampian Co-ordinators: Lead Paediatric Diabetes
More informationAppendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children
Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major
More informationPlease inform the Diabetes Nurse Specialist that this patient has been admitted within 24hrs of admission.
Adult Diabetic Ketoacidosis Care Bundle (V1. Issued October 2014 Review October 2015) Improving patient care This pack includes: DKA Management Guideline Name: (Patient Addressograph) DOB: Hospital No:
More informationSuspected Pulmonary embolus Ambulatory Pathway. Document Title. Date Issued/Approved: Date Valid From: 11/11/17. Date Valid To: 11/05/18
POLICY UNDER REVIEW Please note that this policy is under review. It does, however, remain current Trust policy subject to any recent legislative changes, national policy instruction (NHS or Department
More informationEffective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine
Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This
More informationNursing Management Pre /Post Thrombolysis in Stroke
Craigavon Area Hospital Guidelines for Nursing Management Pre /Post Thrombolysis in Stroke 1. A senior nurse in the stroke unit will be required to monitor the patients condition post Thrombolysis on a
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationAripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)
1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated
More informationManaging your pain at home after surgery. Information for patients
Managing your pain at home after surgery Information for patients Managing your pain at home after surgery This leaflet has been written in order to give you some advice regarding your pain management
More informationAzathioprine and Mercaptopurine
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationSHARED CARE AGREEMENT: MELATONIN (CHILDREN)
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate
More informationPatient guide to Capecitabine chemotherapy with radiotherapy for rectal cancer
Patient Name: Patient guide to chemotherapy with radiotherapy for rectal cancer Chemotherapy This guide should only be given to patients who have been prescribed capecitabine chemotherapy in conjunction
More information02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical POOLE HOSPITAL NHS FOUNDATION TRUST
Service Specification No. Service Commissioner Leads 02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical Provider Lead POOLE HOSPITAL NHS FOUNDATION TRUST Period 1 April 2013 to 31
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationMethylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1
More informationCOALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510
COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510 Effective Date: August 31, 2006 SUBJECT: CARE OF THE INDIVIDUAL RECEIVING CLOZAPINE 1. GENERAL: Clozapine
More informationPolicy for the safe use of oral methotrexate
Policy for the safe use of oral methotrexate Policy Checklist Name of Policy: Purpose of Policy: Directorate responsible for Policy Name & Title of Author: Does this meet criteria of a Policy? Staff side
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationCAPRELSA. (vandetanib)
CAPRELSA (vandetanib) This medicine is subject to additional monitoring. This will allow quick identication of new safety information. You can help by reporting any side effects you may get. See side effects
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More informationPrescription of High Dose Antipsychotic Medication
Subject (M1) Title Medicine Prescription of High Dose Antipsychotic Medication Manual Mental Health Procedure No M1-P-2-MH Department Pharmacy Distribution All Author Rae McKnight Review 4 Reviewer Jonathan
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationPATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY Version Number: 5 Patient Group Direction drawn up by: Name Ray Lyon Dr Al Amaladoss
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationShared Care Guideline Metolazone for fluid management in CKD (Adults)
Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility
More informationSHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN
SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the
More informationPathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
More informationTrust Guideline for the Management of: Condition or Procedure in Adults and / or Children
Trust Guideline for the Management of: Condition or Procedure in Adults and / or Children A clinical guideline recommended For use in: By: For: Division responsible for document: Key words: Name of document
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationPatient Group Direction for the Supply of Orlistat (Xenical) from Designated Community Pharmacies
Patient Group Direction for the Supply of Orlistat (Xenical) from Designated Community Pharmacies Written by: Sheila Brown, Prescribing Adviser Date: September 2006 Reviewed by: Date: Ratified by: East
More informationVersion Number: 5. Patient Group Direction drawn up by: Chief Pharmacist - Strategy. Group direction authorised by:
PATIENT GROUP DIRECTION (PGD) FOR THE INPATIENT ADMINISTRATION OF ORAL LORAZEPAM TO WORKING AGE AND OLDER PEOPLE (includes persons in a Place of Safety suite) Version Number: 5 Patient Group Direction
More informationFRACTURED NECK OF FEMUR CLINICAL PATHWAY
FRACTURED NECK OF FEMUR CLINICAL PATHWAY Patient s... Hospital No. Date... Information Taken By. Designation History of Injury Date and of Event Clinical Assessment of Injury Affected Limb Right Left Reason:
More informationSOUTH THAMES CHILDREN S CANCER NETWORK GROUP. REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014
SOUTH THAMES CHILDREN S CANCER NETWORK GROUP REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014 Contents 1. Leukaemia Referral, Diagnostic and Staging Guidelines 2. Lymphoma Referral,
More informationCLE ABSTRACT INTRODUCTION SUBJECTS AND METHODS. Standards (National) JPPS 2011; 8(2): AUDIT
JPPS 2011; 8(2): 84-89 AUDIT MONITORING THE PATIENTS ON HIGH DOSE ANTIPSYCHOTIC MEDICATIONS, A STANDARD BASED CLINICAL AUDIT CYCLE CLE ABSTRACT Mehboob Yaqub, Yasir Jassam, Grace Fergusson Objective: To
More information